Osiyemi O, et al. - In view of the observation that physiologic changes during pregnancy could impact the pharmacokinetics of drugs, researchers conducted a phase 3b, multicenter, open-label study assessing the pharmacokinetics, antiviral activity, and safety of rilpivirine in pregnant women with Human immunodeficiency virus (HIV)-1 infection. During pregnancy, a decreased rilpivirine exposure was observed. Despite this, the treatment was effective in preventing mother-to-child transmission and suppressing HIV-1 RNA in pregnant women. Thereby suggesting that for HIV-1–infected pregnant women, rilpivirine 25 mg once daily, as part of individualized combination antiretroviral therapy, could be an appropriate option.